G12 - Dabigatran presentation

G12 - Dabigatran presentation - Dabigatran Is technology...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: Dabigatran: Is technology making pharmacists redundant in anti- coagulation clinics? Stephanie Chauv Michelle Hughes Jennifer Lee Teri Phan Lily Wong Group 12 Introduction: Dabigatran • Pradaxa – Made by Boehringer Ingelheim (Germany) – First anti-coagulant drug approved in the US in more than 50 years… • Does NOT require monitoring – Will anti-coagulation clinics become obsolete? Significance: Dabigatran vs. Warfarin Dabigatran Warfarin MOA-Competitive direct thrombin inhibitor-Vitamin K antagonist; Inhibits synthesis of coagulation factors Drug-Drug Interactions PGP inducers (Rifampin, verapamil, ketoconazole) Many… Dietary Interactions Minimal Many… Adverse Reactions Bleeding, hypersensitivity, GI distress, Myocardial Infarction Many… Requires monitoring? No (Wider Therapeutic Index) Regular INR testing (Narrow Therapeutic Index) Other Important Differences No Antidote!...
View Full Document

This note was uploaded on 09/14/2011 for the course PHARM 1 taught by Professor Staff during the Spring '11 term at UCSD.

Page1 / 10

G12 - Dabigatran presentation - Dabigatran Is technology...

This preview shows document pages 1 - 4. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online